Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Lee's Pharm Acquires China Rights to GC Pharma Anticoagulant

publication date: Feb 14, 2018

Lee's Pharm of Hong Kong in-licensed Greater China rights to an investigational anticoagulant being developed by Korea's GC Pharma (formerly known as Green Cross). Lee's will also develop the anticoagulant, an oral Factor Xa inhibitor, in other Southeast Asian countries. GC Pharma will receive an upfront payment along with milestones and royalties, though specific details were not disclosed. Lee's is active in China's anticoagulant space, with one marketed product and several others in development. More details....

Stock Symbols: (HK: 0950) (KRX: 006280) 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here